Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors

Background Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hematological malignancies. Optimization is still required for its application in solid tumors. Here, the lack of cancer-specific structures along with tumor heterogeneity represent a critical barrier to saf...

Full description

Bibliographic Details
Main Authors: Marion Subklewe, Christian Klein, Sebastian Kobold, Pablo Umana, Stefan Endres, Christian Jost, Mohamed-Reda Benmebarek, Anne Freimoser-Grundschober, Sophia Stock, Anna-Kristina Kluever, Diana Darowski, Kay-Gunnar Stubenrauch, Joerg Benz, Ekkehard Moessner
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/7/e005054.full

Internet

https://jitc.bmj.com/content/10/7/e005054.full

Similar Items